Actively Recruiting
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
Led by Keymed Biosciences Co.Ltd · Updated on 2025-11-17
246
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
CONDITIONS
Official Title
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand the study and voluntarily sign a written informed consent form
- Completed the week 18 evaluation in the parent study CM512-101102 or the End of Study visit in the parent study CM512-100001
You will not qualify if you...
- Insufficient washout period from previous therapy
- Any condition deemed by the investigator to make participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
Q
Qian Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here